Premio FHOEMO – SEIOMM 2013
PREVALENCIA DE OSTEOPOROSIS, FRACTURAS VERTEBRALES E HIPOVITAMINOSIS D EN MUJERES POSTMENOPÁUSICAS QUE VIVEN EN UN HÁBITAT RURAL Ver resolución aquí.
Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis
J Clin Endocrinol Metab. 2015 Nov;100(11):4208-14. doi: 10.1210/jc.2015-2829. Epub 2015 Sep 10 CONCLUSIONS: These findings lead us to conclude that premenopausal women with IOP, particularly those over 40, may require antiresorptive treatment to prevent bone … Leer más
Circulating monocytes: an appropriate model for bone-related study
Osteoporos Int. 2015 Nov;26(11):2561-72. doi: 10.1007/s00198-015-3250-7. Epub 2015 Jul 21. In particular, we discuss the close relationship between PBMs and osteoclasts, and highlight the utility of PBMs in study the pathophysiological mechanisms underlying various skeletal … Leer más
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial
A raltegravir-based regimen was associated with significantly less loss of bone mineral density than a standard regimen containing tenofovir disoproxil fumarate, and might be a treatment option for patients at high risk of osteopenia or … Leer más
Body fat loss induced by calcium in co-supplementation with conjugated linoleic acid is associated with increased expression of bone formation genes in adult mice
Overall, in addition to the weight loss promoting properties of calcium, on its own or co-supplemented with conjugated linoleic acid, our results support beneficial effects on bone metabolism in mice.
Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?
Our results suggest that serum levels of myostatin and irisin are related in patients with type 2 diabetes. Triglyceride and glucose levels could modulate myostatin and irisin concentrations as a compensatory mechanism to improve the … Leer más
The role of serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery
These data show that the osteoprotegerin and receptor-activator of nuclear factor-κB ligand system is associated with bone markers and bone mineral density at the lumbar spine after obesity surgery.
Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
Treatment with denosumab increases lumbar and femoral BMD and decreases bone turnover markers in individuals with recent SCI. This drug may be a promising therapeutic option in SCI-related osteoporosis.
